Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319168 | 0.86 | HRH4 (0.65) | HRH4HRH3CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL19004851 | 0.82 | AKT1 (0.47) | HRH4CYP2C19TSHRMAP4K4 | |
| SCHEMBL807296 | 0.82 | SMN1; SMN2 (0.50) | HRH4TSHRMAP4K4 | |
| SCHEMBL30579439 | 0.82 | SMN1; SMN2 (0.50) | HRH4TSHRMAP4K4 | |
| SCHEMBL4953660 | 0.81 | HRH4 (0.55) | HRH4HRH3CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL5889085 | 0.81 | SMN1; SMN2 (0.53) | HRH4CYP1A2ALDH1A1TSHRMAP4K4 | |
| SCHEMBL1775874 | 0.81 | HRH4 (0.64) | HRH4HRH3CYP1A2ALDH1A1HSD17B10 | |
| SCHEMBL2075583 | 0.81 | LRRK2 (0.46) | HRH4HRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL2075530 | 0.81 | KIT (0.48) | HRH3ALDH1A1KDM4EMAPT | |
| SCHEMBL6803952 | 0.80 | KDR (0.51) | HRH4ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2023-03-28 | — | — | US | disclosed |
| CN-111269215-B | Nitrogen-containing heterocyclic organic compound and preparation method and application thereof | 中科利健制药(广州)有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-111269215-A | Nitrogen-containing heterocyclic organic compound and preparation method and application thereof | 中科利健制药(广州)有限公司 | 2020-06-12 | — | — | CN | disclosed |
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| CN-105418592-A | Substituted pyrimidine compounds and application thereof | UNIV EAST CHINA SCIENCE & TECH | 2016-03-23 | — | — | CN | disclosed |
| WO-2015091584-A1 | THIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS TYK2 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2013041539-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20100280012-A1 | AZAAZULENE COMPOUNDS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-11-04 | — | — | US | disclosed |
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1341540-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612604-B2 | Methods of treating cancer with PLK4 inhibitors | PLK4, PLK2, PLK3 | HRH4 4689/4885HRH3 4350/4885CYP1A2 4600/4885 |
| US-20100280012-A1 | AZAAZULENE COMPOUNDS | AZI2, CYP51A1, CYP3A5 | HRH4 2554/4885HRH3 3772/4885CYP1A2 34/4885 |
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | HRH4 4015/4885HRH3 3514/4885CYP1A2 4812/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | HRH4 4015/4885HRH3 3514/4885CYP1A2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.